Oncology Medical News about advanced melanoma;LDH correlation;survival

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
European Journal of Cancer, 05/15/09

Agarwala SS et al. - In a report to assess LDH correlation with survival in advanced melanoma from 2 large, randomised trials, it was shown that lactate dehydrogenase (LDH) should be considered regardless of tumour size or disease site.

Methods

Baseline LDH values in Study GM301 treatment groups were combined and analysed using cutoffs above and below 1 × ULN.
Baseline LDH in EORTC study 18951 (dacarbazine, cisplatin, interferon-alfa-2b with/without interleukin-2 in advanced melanoma) was independently analysed using the same approach.
In Study GM301, the relation between treatment effect and LDH, treatment effect and tumour size, LDH and tumour size, and LDH and disease site were determined.

Results

In Study GM301 (N = 760) and Study 18951 (N = 325), LDH was within the upper range of normal for a large number of pts.
This was not exhibited in the general population, suggesting such values may be elevated rather than normal in melanoma.
A highly ordered and monotonic relationship was apparent between LDH and survival: survival worsened as LDH became more elevated, even when LDH remained within normal range.
LDH and tumour size were poorly correlated; elevated LDH was not associated with any 1 disease site.
LDH was highly predictive of oblimersen effect.

<< Previous
A gene expression predictor of response to EGFR-targeted therapy...

Next >>
Phase I-IIa multicenter dose-escalation study of ezatiostat...

Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/09 Relevance Score: 69%

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
British Journal of Cancer, 11/04/09 Relevance Score: 67%

Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma
European Journal of Cancer, 10/29/09 Relevance Score: 66%

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma
Investigational New Drugs, 10/23/09 Relevance Score: 66%

In vivo, Noninvasive, Label-Free Detection and Eradication of Circulating Metastatic Melanoma Cells Using Two-Color Photoacoustic Flow Cytometry with a Diode Laser
Cancer Research, 10/20/09 Relevance Score: 66%